400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / MAPK/ERK Pathway / p38 MAPK / 2-(2,4-Difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
CAS No.: 745833-23-2
Synonyms: VX-702
VX-702 is a highly selective inhibitor of p38α MAPK with IC50 of 4 -20 nM.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00205478 | Rheumatoid Arthritis | Phase 2 | Completed | - | - |
NCT00395577 | Rheumatoid Arthritis | Phase 2 | Completed | - | Bulgaria ... more >> Call For Information Dimitrovgrad, Bulgaria Call For Information Pleven, Bulgaria Call For Information Sofia, Bulgaria Call For Information Veliko Tarnovo, Bulgaria Croatia Call For Information Osijek, Croatia Call For Information Zagreb, Croatia Former Serbia and Montenegro Call For Information Belgrade, Former Serbia and Montenegro Call For Information Niska Banja, Former Serbia and Montenegro Call For Information Zemun, Former Serbia and Montenegro Poland Call For Information Bytom, Poland Call For Information Krakow, Poland Call for Information Torun, Poland Call For Information Zyrardow, Poland Russian Federation Call For Information Novosibirsk, Russian Federation Call For Information Saratov, Russian Federation Call For Information St. Petersburg, Russian Federation Slovenia Call For Information Ljubljana, Slovenia Collapse << |
实验方案
技术信息
CAS号 | 745833-23-2 | 储存条件 |
|
|||||||||||||
分子式 | C19H12F4N4O2 | 运输 | 蓝冰 | |||||||||||||
分子量 | 404.32 | 别名 | VX-702 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
HOP-62 cell | - | Growth inhibition assay | - | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=0.01543 μM | SANGER |
human A2780 cell | - | Growth inhibition assay | - | Inhibition of human A2780 cell growth in a cell viability assay, IC50=21.8225 μM | SANGER |
human A388 cell | - | Growth inhibition assay | - | Inhibition of human A388 cell growth in a cell viability assay, IC50=7.80384 μM | SANGER |
human A4-Fuk cell | - | Growth inhibition assay | - | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=6.43662 μM | SANGER |
human A549 cell | - | Growth inhibition assay | - | Inhibition of human A549 cell growth in a cell viability assay, IC50=21.2811 μM | SANGER |
human AGS cell | - | Growth inhibition assay | - | Inhibition of human AGS cell growth in a cell viability assay, IC50=0.15251 μM | SANGER |
human BV-173 cell | - | Growth inhibition assay | - | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=0.11386 μM | SANGER |
human CAL-54 cell | - | Growth inhibition assay | - | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50=16.73 μM | SANGER |
human COLO-684 cell | - | Growth inhibition assay | - | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=5.58165 μM | SANGER |
human COR-L88 cell | - | Growth inhibition assay | - | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50=0.3348 μM | SANGER |
human CP66-MEL cell | - | Growth inhibition assay | - | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=2.93559 μM | SANGER |
human CTB-1 cell | - | Growth inhibition assay | - | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=8.17825 μM | SANGER |
human CTV-1 cell | - | Growth inhibition assay | - | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=0.18389 μM | SANGER |
human D-542MG cell | - | Growth inhibition assay | - | Inhibition of human D-542MG cell growth in a cell viability assay, IC50=6.39272 μM | SANGER |
human DB cell | - | Growth inhibition assay | - | Inhibition of human DB cell growth in a cell viability assay, IC50=15.8513 μM | SANGER |
human DEL cell | - | Growth inhibition assay | - | Inhibition of human DEL cell growth in a cell viability assay, IC50=2.20704 μM | SANGER |
human DU-145 cell | - | Growth inhibition assay | - | Inhibition of human DU-145 cell growth in a cell viability assay, IC50=0.14554 μM | SANGER |
human DU-4475 cell | - | Growth inhibition assay | - | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50=5.05565 μM | SANGER |
human ECC10 cell | - | Growth inhibition assay | - | Inhibition of human ECC10 cell growth in a cell viability assay, IC50=0.65389 μM | SANGER |
human EM-2 cell | - | Growth inhibition assay | - | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=15.2841 μM | SANGER |
human ESS-1 cell | - | Growth inhibition assay | - | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=5.29179 μM | SANGER |
human EW-18 cell | - | Growth inhibition assay | - | Inhibition of human EW-18 cell growth in a cell viability assay, IC50=0.74679 μM | SANGER |
human EW-3 cell | - | Growth inhibition assay | - | Inhibition of human EW-3 cell growth in a cell viability assay, IC50=0.66611 μM | SANGER |
human G-361 cell | - | Growth inhibition assay | - | Inhibition of human G-361 cell growth in a cell viability assay, IC50=1.49519 μM | SANGER |
human HAL-01 cell | - | Growth inhibition assay | - | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=3.27918 μM | SANGER |
human HCC2218 cell | - | Growth inhibition assay | - | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=0.49728 μM | SANGER |
human HL-60 cell | - | Growth inhibition assay | - | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=7.52212 μM | SANGER |
human HMV-II cell | - | Growth inhibition assay | - | Inhibition of human HMV-II cell growth in a cell viability assay, IC50=1.77184 μM | SANGER |
human HT-29 cell | - | Growth inhibition assay | - | Inhibition of human HT-29 cell growth in a cell viability assay, IC50=13.9111 μM | SANGER |
human IGROV-1 cell | - | Growth inhibition assay | - | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=2.43188 μM | SANGER |
human JAR cell | - | Growth inhibition assay | - | Inhibition of human JAR cell growth in a cell viability assay, IC50=7.84923 μM | SANGER |
human K5 cell | - | Growth inhibition assay | - | Inhibition of human K5 cell growth in a cell viability assay, IC50=0.22917 μM | SANGER |
human KMOE-2 cell | - | Growth inhibition assay | - | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=14.6178 μM | SANGER |
human KU812 cell | - | Growth inhibition assay | - | Inhibition of human KU812 cell growth in a cell viability assay, IC50=0.12488 μM | SANGER |
human KY821 cell | - | Growth inhibition assay | - | Inhibition of human KY821 cell growth in a cell viability assay, IC50=0.39603 μM | SANGER |
human L-363 cell | - | Growth inhibition assay | - | Inhibition of human L-363 cell growth in a cell viability assay, IC50=7.79252 μM | SANGER |
human LAMA-84 cell | - | Growth inhibition assay | - | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=2.71284 μM | SANGER |
human MDA-MB-361 cell | - | Growth inhibition assay | - | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=4.43158 μM | SANGER |
human MOLT-13 cell | - | Growth inhibition assay | - | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=0.15981 μM | SANGER |
human MOLT-4 cell | - | Growth inhibition assay | - | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=4.99193 μM | SANGER |
human MS-1 | - | Growth inhibition assay | - | Inhibition of human MS-1 cell growth in a cell viability assay, IC50=7.83465 μM | SANGER |
human MV-4-11 cell | - | Growth inhibition assay | - | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=5.71199 μM | SANGER |
human NB14 cell | - | Growth inhibition assay | - | Inhibition of human NB14 cell growth in a cell viability assay, IC50=17.6395 μM | SANGER |
human NCI-H1092 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50=14.318 μM | SANGER |
human NCI-H1299 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=5.53033 μM | SANGER |
human NCI-H1770 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H1770 cell growth in a cell viability assay | SANGER |
human NCI-H209 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=0.1758 μM | SANGER |
human NCI-H510A cell | - | Growth inhibition assay | - | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50=2.92526 μM | SANGER |
human NCI-H526 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=7.59801 μM | SANGER |
human NCI-H69 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50=0.09941 μM | SANGER |
human NCI-H720 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=0.01682 μM | SANGER |
human NCI-H82 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50=3.89305 μM | SANGER |
human NY cells | - | Growth inhibition assay | - | Inhibition of human NY cell growth in a cell viability assay, IC50=4.27637 μM | SANGER |
human RPMI-7951 cell | - | Growth inhibition assay | - | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50=19.1783 μM | SANGER |
human RPMI-8226 cell | - | Growth inhibition assay | - | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50=3.82376 μM | SANGER |
human RS4-11 cell | - | Growth inhibition assay | - | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=3.70573 μM | SANGER |
human RT-112 cell | - | Growth inhibition assay | - | Inhibition of human RT-112 cell growth in a cell viability assay, IC50=15.3984 μM | SANGER |
human SBC-1 cell | - | Growth inhibition assay | - | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=0.2362 μM | SANGER |
human SK-MEL-24 cell | - | Growth inhibition assay | - | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=33.0311 μM | SANGER |
human SK-NEP-1 cell | - | Growth inhibition assay | - | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=11.3038 μM | SANGER |
human SK-OV-3 cell | - | Growth inhibition assay | - | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=2.61697 μM | SANGER |
human T47D cell | - | Growth inhibition assay | - | Inhibition of human T47D cell growth in a cell viability assay, IC50=21.2243 μM | SANGER |
human TI-73 cell | - | Growth inhibition assay | - | Inhibition of human TI-73 cell growth in a cell viability assay, IC50=8.0622 μM | SANGER |
human UACC-257 cell | - | Growth inhibition assay | - | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=1.20326 μM | SANGER |
JVM-2 cell | - | Growth inhibition assay | - | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50=0.083 μM | SANGER |
KARPAS-45 cell | - | Growth inhibition assay | - | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=0.14826 μM | SANGER |
LU-139 cell | - | Growth inhibition assay | - | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=0.19435 μM | SANGER |
ML-2 cell | - | Growth inhibition assay | - | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=0.22661 μM | SANGER |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00205478 | Rheumatoid Arthritis | Phase 2 | Completed | - | - |
NCT00395577 | Rheumatoid Arthritis | Phase 2 | Completed | - | Bulgaria ... more >> Call For Information Dimitrovgrad, Bulgaria Call For Information Pleven, Bulgaria Call For Information Sofia, Bulgaria Call For Information Veliko Tarnovo, Bulgaria Croatia Call For Information Osijek, Croatia Call For Information Zagreb, Croatia Former Serbia and Montenegro Call For Information Belgrade, Former Serbia and Montenegro Call For Information Niska Banja, Former Serbia and Montenegro Call For Information Zemun, Former Serbia and Montenegro Poland Call For Information Bytom, Poland Call For Information Krakow, Poland Call for Information Torun, Poland Call For Information Zyrardow, Poland Russian Federation Call For Information Novosibirsk, Russian Federation Call For Information Saratov, Russian Federation Call For Information St. Petersburg, Russian Federation Slovenia Call For Information Ljubljana, Slovenia Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网